Massimiliano Gnecchi

List of Publications by Year
in descending order

114 papers	10,277 citations	117625 34 h-index	38395 95 g-index
123 all docs	123 docs citations	123 times ranked	13378 citing authors

#	Article	IF	Citations
1	Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	14
2	Self-perception of acute symptoms in adolescents with COVID-19. Lancet Regional Health - Europe, The, 2022, 16, 100383.	5.6	0
3	Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study. Journal of Cardiovascular Medicine, 2022, 23, 439-446.	1.5	6
4	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. Clinical Research in Cardiology, 2021, 110, 1020-1028.	3.3	32
5	MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes. Cardiovascular Research, 2021, 117, 767-779.	3.8	34
6	NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis. Cardiovascular Research, 2021, 117, 472-483.	3.8	22
7	Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Stem Cells Translational Medicine, 2021, 10, 636-642.	3.3	40
8	Firstâ€inâ€man case of nonâ€invasive proton radiotherapy for the treatment of refractory ventricular tachycardia in advanced heart failure. European Journal of Heart Failure, 2021, 23, 195-196.	7.1	16
9	Has hyperglycemia a different prognostic role in STEMI patients with or without diabetes?. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 528-531.	2.6	9
10	Elevated serum uric acid is associated with a greater inflammatory response and with short- and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 608-614.	2.6	22
11	Precision Medicine and cardiac channelopathies: when dreams meet reality. European Heart Journal, 2021, 42, 1661-1675.	2.2	34
12	Elevated serum uric acid is a predictor of contrast associated acute kidney injury in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2140-2143.	2.6	12
13	Neutrophil Extracellular Traps Induce the Epithelial-Mesenchymal Transition: Implications in Post-COVID-19 Fibrosis. Frontiers in Immunology, 2021, 12, 663303.	4.8	45
14	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. Europace, 2021, 23, 1603-1611.	1.7	34
15	The prognostic value of serial troponin measurements in patients admitted for COVIDâ€19. ESC Heart Failure, 2021, 8, 3504-3511.	3.1	25
16	Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19. International Journal of Infectious Diseases, 2021, 108, 270-273.	3.3	6
17	Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants. Circulation Genomic and Precision Medicine, 2021, 14, e003289.	3.6	10
18	Extracellular vesicles fail to trigger the generation of new cardiomyocytes in chronically infarcted hearts. Theranostics, 2021, 11, 10114-10124.	10.0	10

#	Article	IF	Citations
19	Barriers associated with emergency medical service activation in patients with ST-segment elevation acute coronary syndromes. Internal and Emergency Medicine, 2021, , 1.	2.0	1
20	Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19. Frontiers in Physiology, 2021, 12, 730127.	2.8	4
21	Favorable effect of glycoprotein IIbIIIa inhibitors among STEMI patients treated with primary PCI and incomplete ST resolution. Platelets, 2020, 31, 48-54.	2.3	5
22	Neutrophil to platelet ratio: A novel prognostic biomarker in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. European Journal of Preventive Cardiology, 2020, 27, 2338-2340.	1.8	17
23	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi006-A from a patient affected by an autosomal recessive form of long QT syndrome type 1. Stem Cell Research, 2020, 42, 101658.	0.7	4
24	Risk factors for primary ventricular fibrillation during a first myocardial infarction: Clinical findings from PREDESTINATION (PRimary vEntricular fibrillation and suDden dEath during firST) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 53	1.7	10
25	Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis. Journal of Cardiovascular Medicine, 2020, 21, 570-576.	1.5	7
26	Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms, 2020, 8, 977.	3.6	41
27	Impact of heart failure on the clinical course and outcomes of patients hospitalized for <scp>COVID</scp>â€19. Results of the <scp>Cardioâ€COVIDâ€Italy</scp> multicentre study. European Journal of Heart Failure, 2020, 22, 2238-2247.	7.1	99
28	How do Extracellular Vesicles Protect the Ischemic Myocardium?. Cytotherapy, 2020, 22, S189.	0.7	0
29	Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Internal and Emergency Medicine, 2020, 15, 1457-1465.	2.0	32
30	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1274.	6.1	157
31	Leptin affects the inflammatory response after STEMI. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 922-924.	2.6	4
32	Serum uric acid may modulate the inflammatory response after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Journal of Cardiovascular Medicine, 2020, 21, 337-339.	1.5	14
33	Myocarditis in a 16-year-old boy positive for SARS-CoV-2. Lancet, The, 2020, 395, e116.	13.7	52
34	Angiography- vs. physiology-guided complete revascularization in patients with ST-elevation myocardial infarction and multivessel disease: who is the better gatekeeper in this setting? A meta-analysis of randomized controlled trials. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 199-200.	4.0	11
35	Cardiac Repolarization and Stem Cells: An Emerging Path Toward Precision Medicine. , 2020, , 87-107.		1
36	Mesenchymal Stromal Cell Secretome for Tissue Repair. , 2020, , 641-666.		2

#	Article	IF	Citations
37	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. European Heart Journal, 2020, 41, 2083-2088.	2.2	716
38	386â€ƒAchieving Ldl Cholesterol Target In A Real-World Secondary Prevention Cohort: When Two Is Better Than One. European Heart Journal Supplements, 2020, 22, N132-N134.	0.1	0
39	The unfavourable inflammatory response in elderly patients after myocardial infarction: should we talk of â€˜dysflammagingâ€™?. Journal of Cardiovascular Medicine, 2020, 21, 340-342.	1.5	1
40	D-dimer for the prediction of left atrial appendage thrombosis: daydream or reality? A meta-analysis. European Heart Journal, 2020, 41, .	2.2	0
41	Generation of two human induced pluripotent stem cell (hiPSC) lines from a long QT syndrome South African founder population. Stem Cell Research, 2019, 39, 101510.	0.7	3
42	Tuning Tissue Ingrowth into Proangiogenic Hydrogels via Dual Modality Degradation. ACS Biomaterials Science and Engineering, 2019, 5, 5430-5438.	5.2	5
43	Smokerâ€™s paradox in ST-elevation myocardial infarction: Role of inflammation and platelets. Hellenic Journal of Cardiology, 2019, 60, 397-399.	1.0	2
44	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation. Stem Cell Research, 2019, 37, 101437.	0.7	1
45	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene. Stem Cell Research, 2019, 36, 101416.	0.7	2
46	Early Complete Revascularization in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. Canadian Journal of Cardiology, 2019, 35, 1047-1057.	1.7	8
47	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation. Stem Cell Research, 2019, 37, 101431.	0.7	2
48	From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. European Heart Journal, 2019, 40, 1832-1836.	2.2	69
49	Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells. Arrhythmia and Electrophysiology Review, 2019, 8, 105-110.	2.4	36
50	Mesenchymal Stromal Cell Secretome for Tissue Repair. , 2019, , 1-26.		1
51	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene. Stem Cell Research, 2018, 29, 157-161.	0.7	3
52	Synthetic extracellular matrix mimic hydrogel improves efficacy of mesenchymal stromal cell therapy for ischemic cardiomyopathy. Acta Biomaterialia, 2018, 70, 71-83.	8.3	41
53	Optimized lentiviral transduction of human amniotic mesenchymal stromal cells. Pharmacological Research, 2018, 127, 49-57.	7.1	4
54	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1. Stem Cell Research, 2018, 29, 170-173.	0.7	6

#	Article	IF	Citations
55	Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. European Heart Journal, 2018, 39, 1446-1455.	2.2	100
56	Different pro-angiogenic potential of Î³-irradiated PBMC-derived secretome and its subfractions. Scientific Reports, 2018, 8, 18016.	3.3	33
57	Cell Therapy for Heart Regeneration: Learning from the Past to Build a Brighter Future. Stem Cells Translational Medicine, 2018, 7, 702-704.	3.3	9
58	The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. International Journal of Cardiology, 2017, 240, 367-371.	1.7	28
59	Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias. International Journal of Cardiology, 2017, 237, 49-52.	1.7	33
60	Comparison of Outcomes of Staged Complete Revascularization Versus Culprit Lesionâ€“Only Revascularization for ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. American Journal of Cardiology, 2017, 119, 508-514.	1.6	8
61	Prognostic Impact of in-Hospital-Bleeding in Patients With ST-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 120, 1734-1741.	1.6	12
62	Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Scientific Reports, 2017, 7, 15661.	3.3	63
63	Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovascular Research, 2017, 113, 531-541.	3.8	110
64	Protocols for in vitro Differentiation of Human Mesenchymal Stem Cells into Osteogenic, Chondrogenic and Adipogenic Lineages. Methods in Molecular Biology, 2016, 1416, 149-158.	0.9	82
65	Testing the Paracrine Properties of Human Mesenchymal Stem Cells Using Conditioned Medium. Methods in Molecular Biology, 2016, 1416, 445-456.	0.9	12
66	Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair. Methods in Molecular Biology, 2016, 1416, 123-146.	0.9	318
67	Modeling Heart Failure in Danon Disease Using Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Cytotherapy, 2016, 18, S12.	0.7	0
68	Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes Carrying CALM1-F142l Mutation Recapitulate LQTS Phenotype in Vitro. Biophysical Journal, 2016, 110, 263a.	0.5	0
69	Optimized Method to Determine Infarct Size and Stem Cell Engraftment in Rodent Hearts Subjected to Ischemia-Reperfusion Injury. Cytotherapy, 2016, 18, S80-S81.	0.7	0
70	Improving the Cardioprotective and Regenerative Properties of Bone Marrow Derived Mesenchymal Stem Cells Through the Overexpression of IGF1 and BMP2. Cytotherapy, 2016, 18, S81.	0.7	0
71	Donor Age Impairs the Capacity of Human Mesenchymal Stromal Cells to Repair Cardiac and Renal Damage. Cytotherapy, 2016, 18, S16.	0.7	0
72	Symptomatic and Asymptomatic Discrimination by Single Nucleotide Polymorphisms in LQTS2 Patients: A DNA-Based Patient Stratification. Cytotherapy, 2016, 18, S151.	0.7	0

#	Article	IF	Citations
73	Transfection of Embryoid Bodies with miRNA Precursors to Induce Cardiac Differentiation. Bio-protocol, 2016, 6, .	0.4	0
74	Novel degradable heparin hydrogel improves the engraftment and therapeutic effect of mesenchymal stromal cells in ischemic heart disease. Cytotherapy, 2015, 17, S54.	0.7	0
75	Conditioned Medium From Human Amniotic Mesenchymal Stromal Cells Limits Infarct Size and Enhances Angiogenesis. Stem Cells Translational Medicine, 2015, 4, 448-458.	3.3	94
76	microRNA and Cardiac Regeneration. Advances in Experimental Medicine and Biology, 2015, 887, 119-141.	1.6	14
77	Combination of miRNA499 and miRNA133 Exerts a Synergic Effect on Cardiac Differentiation. Stem Cells, 2015, 33, 1187-1199.	3.2	31
78	Paracrine Factors of Human Fetal MSCs Inhibit Liver Cancer Growth Through Reduced Activation of IGF-1R/PI3K/Akt Signaling. Molecular Therapy, 2015, 23, 746-756.	8.2	72
79	Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB Journal, 2015, 29, 4614-4628.	0.5	60
80	Genotype-Phenotype Correlation in Induced Pluripotent Stem Cell (iPSC)Derived Cardiomyocytes Carrying Calmodulin Mutations. Biophysical Journal, 2014, 106, 333a.	0.5	1
81	Rat Experimental Model of Myocardial Ischemia/Reperfusion Injury: An Ethical Approach to Set up the Analgesic Management of Acute Post-Surgical Pain. PLoS ONE, 2014, 9, e95913.	2.5	14
82	Overexpression of growth factors to improve cardiac differentiation of human mesenchymal stem cells derived from the amniotic membrane. European Heart Journal, 2013, 34, P5692-P5692.	2.2	2
83	Mesenchymal Stem Cell Therapy for Heart Disease. , 2013, , 241-270.		7
84	Allogeneic Lethally Irradiated Cord Blood Mononuclear Cells in No-Option Critical Limb Ischemia: A â€œBox of Rainâ€• Stem Cells and Development, 2013, 22, 2806-2812.	2.1	20
85	Novel IRES-based lentivirus co-expressing IGF1 and BMP2 enhances both cardiomyogenesis and cytoprotection of bone marrow-derived mesenchymal stem cells. European Heart Journal, 2013, 34, P1473-P1473.	2.2	0
86	Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality. European Heart Journal, 2013, 34, P4239-P4239.	2.2	0
87	MicroRNA133 and microRNA499 exert synergistic effect on cardiac differentiation. European Heart Journal, 2013, 34, P1460-P1460.	2.2	0
88	Pentraxin-3 and galectin-1 are key mediators of the cardioprotective paracrine effects exerted by fetal mesenchymal stem cells isolated from human placenta. European Heart Journal, 2013, 34, P3271-P3271.	2.2	0
89	The Unstoppable Attraction for Induced Pluripotent Stem Cells. Journal of the American College of Cardiology, 2012, 60, 1001-1004.	2.8	7
90	Mesenchymal stem cell therapy for heart disease. Vascular Pharmacology, 2012, 57, 48-55.	2.1	137

#	Article	IF	Citations
91	What is the Paracrine Effect of Stem Cells?. , 2012, , 219-267.		0
92	Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. Journal of Molecular and Cellular Cardiology, 2011, 50, 280-289.	1.9	414
93	Vagal Stimulation, Through its Nicotinic Action, Limits Infarct Size and the Inflammatory Response to Myocardial Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2011, 58, 500-507.	1.9	163
94	Adult Stem Cell-Based Therapy for the Heart. , 2010, , 899-935.		0
95	Early Beneficial Effects of Bone Marrow-Derived Mesenchymal Stem Cells Overexpressing Akt on Cardiac Metabolism After Myocardial Infarction. Stem Cells, 2009, 27, 971-979.	3.2	110
96	Bone Marrow-Derived Mesenchymal Stem Cells: Isolation, Expansion, Characterization, Viral Transduction, and Production of Conditioned Medium. Methods in Molecular Biology, 2009, 482, 281-294.	0.9	227
97	Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy. Circulation Research, 2008, 103, 1204-1219.	4.5	1,809
98	Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1643-1648.	7.1	500
99	Vascular Remodeling in Health and Disease. , 2007, , 1541-1565.		3
100	Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Molecular Therapy, 2006, 14, 840-850.	8.2	454
101	Heme oxygenaseâ€1 (HOâ€1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB Journal, 2006, 20, 207-216.	0.5	118
102	Evidence supporting paracrine hypothesis for Aktâ€modified mesenchymal stem cellâ€mediated cardiac protection and functional improvement. FASEB Journal, 2006, 20, 661-669.	0.5	1,082
103	Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nature Medicine, 2005, 11, 367-368.	30.7	1,512
104	Therapeutic Potential of Endothelial Progenitor Cells in Cardiovascular Diseases. Hypertension, 2005, 46, 7-18.	2.7	199
105	Genetic therapies for cardiovascular diseases. Trends in Molecular Medicine, 2005, 11, 240-250.	6.7	42
106	Liver X receptors Â and Â regulate renin expression in vivo. Journal of Clinical Investigation, 2005, 115, 1913-1922.	8.2	86
107	Angiotensin-converting enzyme insertion/deletion polymorphism and risk of restenosis after directional coronary atherectomy followed by stent implantation. Thrombosis and Haemostasis, 2004, 91, 795-800.	3.4	1
108	Gene and cellâ€based therapies for heart disease. FASEB Journal, 2004, 18, 648-663.	0.5	71

#	Article	IF	Citations
109	Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1761-1774.	2.4	59
110	Cytokine-Induced Mobilization of Circulating Endothelial Progenitor Cells Enhances Repair of Injured Arteries. Circulation, 2004, 110, 2039-2046.	1.6	279
111	Molecular and Cell-Based Therapies for Protection, Rescue, and Repair of Ischemic Myocardium. Circulation, 2004, 109, 2386-2393.	1.6	73
112	Gene- and cell-based therapies for cardiovascular diseases: current status and future directions. European Heart Journal Supplements, 2004, 6, E24-E35.	0.1	3
113	Effectiveness of adjunctive stent implantation following directional coronary atherectomy for treatment of left anterior descending ostial stenosis. American Journal of Cardiology, 2002, 90, 1074-1078.	1.6	17
114	Endothelium-targeted Gene and Cell-based Therapy for Cardiovascular Disease. , 0, , 365-399.		1